Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE
Not Applicable
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Diagnostic Test: MRI
- Registration Number
- NCT03731910
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline
- Scheduled for transarterial radioembolization (TARE)
- sign informed consent
Exclusion Criteria
- Any absolute or relative contra-indication of contrast-enhanced MRI
- History of other local treatment before TARE in 3 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description HCC group MRI Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
- Primary Outcome Measures
Name Time Method Treatment response mRECIST 1 month after last MRI treatment response using mRECIST
- Secondary Outcome Measures
Name Time Method Tumor diffusion 1 months after last MRI measured with diffusion-weighted image sequence
Tumor perfusion 1 months after last MRI measured with dynamic contrast-enhanced imaging
Treatment response LI-RADS 1 months after last MRI treatment response using LI-RADSv 2018 treatment response category
Treatment response volumetric 1 months after last MRI treatment response using volumetric response criteria
Time to Progression 24 months after TARE Time until to definite progression on follow-up images
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of